Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00109512
Status:
COMPLETED
Last Update Posted:
2012-02-22
First Post:
2005-04-28
Brief Title:
Endometriosis Trial Study of NBI-56418 in Endometriosis
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Phase II Randomized Double-Blind Placebo-Controlled Study of NBI-56418 in Endometriosis
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II multicenter randomized double-blind placebo-controlled parallel-group study with subjects randomized to one of three treatment groups placebo 75 mg and 150 mg in a 111 ratio Study drug was administered once daily for 12 weeks After the last dose at the end of Week 12 follow-up continued every 4 weeks for 12 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None